Prof. Dong-Young Noh, An Authority On Breast Cancer,

Appointed As The Co-CEO Of BERTIS

- Has Studied Breast Cancer For More Than 30 Years, And Been Involved In The Development of MASTOCHECK,

A Breast Cancer Early Diagnosis Solution, Which Is The Flagship of BERTIS
- "Will Speed Up Technology Development And Grow BERTIS Into A Global Healthcare Company

Based On My Know-How As A Researcher

<Photo: Noh Dong-Young, Co-CEO of BERTIS>

BERTIS, a company developing early diagnosis technology based on proteomics, announced that Prof. Noh Dong-young, a world-renowned authority on breast cancer, was appointed as co-CEO. Accordingly, BERTIS will have a co-representative system, which will be managed by the existing CEO Seung-man Han and the new CEO Dong-young Noh. 

Prof. Dong-young Noh is an expert who has treated breast cancer patients for more than 30 years and is also the developer of MASTOCHECK. MASTOCHECK is an innovative and convenient test method that can diagnose breast cancer at an early stage with an accuracy of 92% (patent-based) with only 1 ml of blood. Prof. Noh began studies on protein biomarkers as a member of the International Cancer Biomarker Consortium (ICBC) led by Professor Leland H. Hartwell, the winner of the Nobel Prize in Physiology or Medicine in 2008 and conducted repeated verification with B to develop high accuracy MASTOCHECK. 

Prof. Noh was appointed as a professor at Seoul National University Medical School in 1990. He served as the director of the breast center, the director of the cancer center at Seoul National University Hospital, and the vice president of research at Seoul National University, and the current director at CHA University Gangnam Medical Center, and the clinical professor at the breast center. With Prof. Noh's expertise in breast cancer, he is currently chairman of the Korea Cancer Association and chairman of the Korea Breast Cancer Foundation. With the appointment of the CEO this time, Mr. Noh will concurrently hold the position of the director of the CHA University Gangnam Medical Center and the position of the CEO of BERTIS.

BERTIS said, "We expect that Mr. Noh's experiences accumulated through years of technical research and clinical field will accelerate the development of our various diagnostic technologies." 

Also, Prof. Noh said, "I hope that my research, which started in breast cancer, will bear fruit in BERTIS and become a hope for those suffering from various diseases," and he revealed his ambitions by saying "I will make BERTIS a global proteomics company by adding the know-how as a researcher to Mr. Han."